Submission of Matters to a Vote of Security Holders

Business Context and Reporting Period

This Form 8-K, dated January 30, 2026, reports the results of the Annual and Special Meeting of Stockholders held by Coeptis Therapeutics Holdings, Inc. (the "Company"). The filing details the approval of a merger with Z Squared, a corporate name change to "Z Squared Inc.," and the adoption of a new equity incentive plan. The record date for the meeting was January 2, 2026, with 5,680,111 shares of common stock outstanding.

Key Financial Metrics

The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and stockholder voting results.

Material Changes and Voting Results

Stockholders representing 3,697,558 shares (65.1% of outstanding shares) attended the meeting, constituting a quorum. The following material changes were approved:

  • Merger Approval: Stockholders approved the issuance of common stock in the Merger with Z Squared (Proposal 1), with 3,472,303 votes FOR and 225,250 votes AGAINST.
  • Spin Out Approval: Stockholders approved the spin-out of biopharmaceutical operations other than those conducted through GEAR Therapeutics, Inc. (Proposal 2), with 3,470,423 votes FOR and 225,865 votes AGAINST.
  • Name Change: The corporate name change from Coeptis Therapeutics Holdings, Inc. to "Z Squared Inc." was approved (Proposal 3), with 3,471,316 votes FOR and 226,240 votes AGAINST.
  • Equity Incentive Plan: A new equity incentive plan for the combined company was adopted (Proposal 4) with overwhelming support (3,681,614 FOR vs. 12,291 AGAINST).
  • Board of Directors: Five directors were elected to the board of the combined company, including Bryan Fuerst, Adam Sohn, David Halabu, Michelle Burke, and Kenneth Cooper.
  • Option Repricing: Stockholders approved the repricing or replacement of certain outstanding options (Proposal 6), with 3,453,849 votes FOR and 241,823 votes AGAINST.
  • Auditor Ratification: Astra Audit & Advisory, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
  • Executive Compensation: The non-binding advisory vote on executive compensation was approved (Proposal 8) with 3,691,897 votes FOR and 2,849 votes AGAINST.

Guidance, Outlook, and Risks

The filing does not contain forward-looking guidance, management commentary on future financial performance, or specific risk factors beyond the context of the merger and spin-out transactions. The primary focus is the successful execution of the stockholder vote to effectuate the change of control and corporate restructuring.

Key Facts for Investor Verification

  • Verify the final closing date and terms of the Merger with Z Squared as detailed in the Agreement and Plan of Merger dated April 25, 2025.
  • Confirm the operational structure and timeline for the spin-out of biopharmaceutical operations excluding GEAR Therapeutics, Inc.
  • Monitor the ticker symbol change and trading status following the name change to "Z Squared Inc."
  • Review the specific terms of the repriced or replaced options approved under Proposal 6 to assess potential dilution.
  • Check subsequent filings for the official effective date of the new Board of Directors and the new Equity Incentive Plan.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.